<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585766</url>
  </required_header>
  <id_info>
    <org_study_id>CD-IA-MEDI-551-1102</org_study_id>
    <nct_id>NCT01585766</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ascending intravenous
      (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of
      multiple sclerosis (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multicenter, multinational, randomized, blinded, placebo-controlled,
      dose-escalation study to evaluate the safety and tolerability of IV and SC doses of MEDI-551
      in adult subjects with relapsing forms of MS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2012</start_date>
  <completion_date type="Actual">June 20, 2016</completion_date>
  <primary_completion_date type="Actual">January 2, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From study drug administration (Day 1) through the end of treatment period (Day 169)</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From study drug administration (Day 1) through the long term follow up period (up to 18 months after early discontinuation visit or 24 week treatment period).</time_frame>
    <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs</measure>
    <time_frame>From study drug administration (Day 1) through the end of treatment period (Day 169)</time_frame>
    <description>Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities Reported as TEAEs</measure>
    <time_frame>From study drug administration (Day 1) through the end of treatment period (Day 169)</time_frame>
    <description>Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>The time to reach the maximum observed serum concentration of MEDI-551.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>The maximum observed serum concentration (Cmax) of MEDI-551.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
    <description>The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Subcutaneous Bioavailability (F%) of MEDI-551</measure>
    <time_frame>Predose (Day 1) and Days 4, 8, 15, 29, 57, 85, 113, 141, and 169</time_frame>
    <description>Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute CD20 B-cell Count at Baseline</measure>
    <time_frame>Baseline (Days -28 to -1)</time_frame>
    <description>Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 90 Percent (%) CD20 B-cell Depletion</measure>
    <time_frame>Baseline (Days -28 to -1) to long-term follow-up (LTFU) (Up to 18 months after EDV or 24 Week treatment period)</time_frame>
    <description>Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count</measure>
    <time_frame>Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)</time_frame>
    <description>Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU</measure>
    <time_frame>Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)</time_frame>
    <description>The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Positive for Anti-Drug Antibodies to MEDI-551</measure>
    <time_frame>Days 1, 29, 85 and 169</time_frame>
    <description>A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Multiple Sclerosis, Relapsing Forms</condition>
  <arm_group>
    <arm_group_label>MEDI-551 30 MG-IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 60 MG-SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 100 MG-IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 300 MG-SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 600 MG-IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO-IV-SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551 30 MG-IV</intervention_name>
    <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
    <arm_group_label>MEDI-551 30 MG-IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551 60 MG-SC</intervention_name>
    <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
    <arm_group_label>MEDI-551 60 MG-SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO-IV-SC</intervention_name>
    <description>Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1</description>
    <arm_group_label>PLACEBO-IV-SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551 100 MG-IV</intervention_name>
    <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
    <arm_group_label>MEDI-551 100 MG-IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551 300 MG-SC</intervention_name>
    <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
    <arm_group_label>MEDI-551 300 MG-SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551 600 MG-IV</intervention_name>
    <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
    <arm_group_label>MEDI-551 600 MG-IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed relapsing form of MS (ie, RRMS, SPMS, PRMS, or CIS) according to revised
             2010 McDonald criteria and MRI brain lesions consistent with MS on screening

          -  At least 1 documented relapse within the past 3 years prior to screening

          -  EDSS between 0.0 and 6.5 at screening

          -  Have no more than 20 Gd-enhancing T1 brain lesions detected by cranial MRI scan

        Exclusion Criteria:

          -  Subjects with impaired renal function

          -  Major surgery within 8 weeks of the screening visit

          -  Subjects who are unable to undergo cranial MRI scan

          -  A history of hypersensitivity to Gd-containing MRI contrast agents

          -  Has received within 1 year prior to screening: monoclonal antibodies, experimental
             B-cell depleting agents, or treatment with natalizumab (Tysabri) for greater than 3
             months

          -  Receiving monthly methylprednisone or equivalent glucocorticoid for disease
             modification of a relapsing form of MS

          -  Known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent
             antihistamine, methylprednisolone or equivalent glucocorticoid, or to any component of
             the investigational drug

          -  Diagnosis of PPMS, neuromyelitis optica, or other non-MS variant of neuro-inflammatory
             or demyelinating diseases

          -  Any history of opportunistic infection or the presence of active infection within two
             months prior to screening or any herpes zoster infection that has not resolved within
             12 weeks prior to screening

          -  Any clinically significant findings during the screening phase, including physical,
             neurological, laboratory, or ECG examination as per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Flor</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 9, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <results_first_submitted>June 13, 2017</results_first_submitted>
  <results_first_submitted_qc>February 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MAb, B cell, depletion, RMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted from 30 Jul 2012 to 20 Jun 2016 in United States, Poland, Spain, and Ukraine.</recruitment_details>
      <pre_assignment_details>A total of 56 participants were screened in this study. Out of which 28 participants were enrolled and randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PLACEBO-IV-SC</title>
          <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>MEDI-551 30 Mg-IV</title>
          <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="P3">
          <title>MEDI-551 60 Mg-SC</title>
          <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MEDI-551 100 Mg-IV</title>
          <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="P5">
          <title>MEDI-551 300 Mg-SC</title>
          <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>MEDI-551 600 Mg-IV</title>
          <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population is defined as all participants who received any amount of study drug. One participant in the 30 mg IV dose cohort received an incorrect dose of study drug due to kits not administered according to the IVRS; the participant received MEDI-551 100 mg IV instead of 30 mg on Day 1.</population>
      <group_list>
        <group group_id="B1">
          <title>PLACEBO-IV-SC</title>
          <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>MEDI-551 30 Mg-IV</title>
          <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="B3">
          <title>MEDI-551 60 Mg-SC</title>
          <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MEDI-551 100 Mg-IV</title>
          <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="B5">
          <title>MEDI-551 300 Mg-SC</title>
          <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>MEDI-551 600 Mg-IV</title>
          <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="15.9"/>
                    <measurement group_id="B2" value="42.4" spread="7.8"/>
                    <measurement group_id="B3" value="46.7" spread="16.3"/>
                    <measurement group_id="B4" value="46.5" spread="13.8"/>
                    <measurement group_id="B5" value="56.0" spread="6.1"/>
                    <measurement group_id="B6" value="44.2" spread="10.1"/>
                    <measurement group_id="B7" value="45.4" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0</description>
        <time_frame>From study drug administration (Day 1) through the end of treatment period (Day 169)</time_frame>
        <population>Safety Population is defined as all participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0</description>
          <population>Safety Population is defined as all participants who received any amount of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)</title>
        <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0</description>
        <time_frame>From study drug administration (Day 1) through the long term follow up period (up to 18 months after early discontinuation visit or 24 week treatment period).</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)</title>
          <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs</title>
        <description>Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.</description>
        <time_frame>From study drug administration (Day 1) through the end of treatment period (Day 169)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs</title>
          <description>Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology- Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology- White blood cell count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum chemistry- Liver function test increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum chemistry- Hyponatraemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Sign Abnormalities Reported as TEAEs</title>
        <description>Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.</description>
        <time_frame>From study drug administration (Day 1) through the end of treatment period (Day 169)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities Reported as TEAEs</title>
          <description>Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood pressure increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pressure decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551</title>
        <description>The time to reach the maximum observed serum concentration of MEDI-551.</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551</title>
          <description>The time to reach the maximum observed serum concentration of MEDI-551.</description>
          <population>Safety Population</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.11" upper_limit="0.19"/>
                    <measurement group_id="O2" value="2.98" lower_limit="2.87" upper_limit="6.97"/>
                    <measurement group_id="O3" value="0.07" lower_limit="0.01" upper_limit="0.11"/>
                    <measurement group_id="O4" value="7.92" lower_limit="7.82" upper_limit="8.02"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.11" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of MEDI-551</title>
        <description>The maximum observed serum concentration (Cmax) of MEDI-551.</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of MEDI-551</title>
          <description>The maximum observed serum concentration (Cmax) of MEDI-551.</description>
          <population>Safety Population</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="13.2"/>
                    <measurement group_id="O2" value="6.67" spread="2.88"/>
                    <measurement group_id="O3" value="43.1" spread="11.4"/>
                    <measurement group_id="O4" value="24.7" spread="9.37"/>
                    <measurement group_id="O5" value="248" spread="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551</title>
        <description>The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551</title>
          <description>The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.</description>
          <population>Safety Population</population>
          <units>microgram*day per milliliter(mcg*day/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="NA">Standard deviation was not calculated due to limited sample size (n=2). Two out of five participants received only one dose and 1 participant had insufficient data.</measurement>
                    <measurement group_id="O2" value="197" spread="92.6"/>
                    <measurement group_id="O3" value="1140" spread="278"/>
                    <measurement group_id="O4" value="788" spread="455"/>
                    <measurement group_id="O5" value="6850" spread="1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551</title>
        <description>The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551</title>
          <description>The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.</description>
          <population>Safety Population</population>
          <units>mcg*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440" spread="NA">Standard deviation was not calculated due to limited sample size (n=2). Two out of five participants received only one dose and 1 participant had insufficient data.</measurement>
                    <measurement group_id="O2" value="201" spread="91.5"/>
                    <measurement group_id="O3" value="1150" spread="286"/>
                    <measurement group_id="O4" value="794" spread="453"/>
                    <measurement group_id="O5" value="6950" spread="1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551</title>
        <description>The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551</title>
          <description>The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.</description>
          <population>Safety Population</population>
          <units>mcg*day/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" spread="NA">Standard deviation was not calculated due to limited sample size (n=2). Two out of five participants received only one dose and 1 participant had insufficient data.</measurement>
                    <measurement group_id="O2" value="3.35" spread="1.52"/>
                    <measurement group_id="O3" value="5.75" spread="1.43"/>
                    <measurement group_id="O4" value="2.65" spread="1.51"/>
                    <measurement group_id="O5" value="5.79" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of MEDI-551</title>
        <description>Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of MEDI-551</title>
          <description>Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated</description>
          <population>Safety Population</population>
          <units>mL/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="NA">Standard deviation was not calculated due to limited sample size (n=2). Two out of five participants received only one dose and 1 participant had insufficient data.</measurement>
                    <measurement group_id="O2" value="351" spread="177"/>
                    <measurement group_id="O3" value="181" spread="44.5"/>
                    <measurement group_id="O4" value="457" spread="214"/>
                    <measurement group_id="O5" value="180" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2) of MEDI-551</title>
        <description>The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.</description>
        <time_frame>Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) of MEDI-551</title>
          <description>The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.</description>
          <population>Safety Population</population>
          <units>Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="NA">Standard deviation was not calculated due to limited sample size (n=2). Two out of five participants received only one dose and 1 participant had insufficient data.</measurement>
                    <measurement group_id="O2" value="12.3" spread="1.71"/>
                    <measurement group_id="O3" value="17.7" spread="6.27"/>
                    <measurement group_id="O4" value="15.1" spread="4.31"/>
                    <measurement group_id="O5" value="18.7" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Subcutaneous Bioavailability (F%) of MEDI-551</title>
        <description>Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.</description>
        <time_frame>Predose (Day 1) and Days 4, 8, 15, 29, 57, 85, 113, 141, and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Subcutaneous Bioavailability (F%) of MEDI-551</title>
          <description>Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.</description>
          <population>Safety Population</population>
          <units>Percentage of bioavailability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute CD20 B-cell Count at Baseline</title>
        <description>Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.</description>
        <time_frame>Baseline (Days -28 to -1)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute CD20 B-cell Count at Baseline</title>
          <description>Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.</description>
          <population>Safety Population</population>
          <units>cells/mcL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="99.1"/>
                    <measurement group_id="O2" value="173" spread="36.1"/>
                    <measurement group_id="O3" value="180" spread="108"/>
                    <measurement group_id="O4" value="183" spread="65.5"/>
                    <measurement group_id="O5" value="366" spread="257"/>
                    <measurement group_id="O6" value="201" spread="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 90 Percent (%) CD20 B-cell Depletion</title>
        <description>Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.</description>
        <time_frame>Baseline (Days -28 to -1) to long-term follow-up (LTFU) (Up to 18 months after EDV or 24 Week treatment period)</time_frame>
        <population>Safety Population. No participants in placebo-IV-SC group reached 90% CD20 B-cell depletion.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 90 Percent (%) CD20 B-cell Depletion</title>
          <description>Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.</description>
          <population>Safety Population. No participants in placebo-IV-SC group reached 90% CD20 B-cell depletion.</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="15.0" spread="1.10" lower_limit="13.0" upper_limit="16.0"/>
                    <measurement group_id="O3" value="88.0" spread="50.3" lower_limit="4.00" upper_limit="94.0"/>
                    <measurement group_id="O4" value="25.0" spread="6.19" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O5" value="15.0" spread="4.04" lower_limit="15.0" upper_limit="22.0"/>
                    <measurement group_id="O6" value="14.5" spread="5.65" lower_limit="4.00" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count</title>
        <description>Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.</description>
        <time_frame>Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)</time_frame>
        <population>Safety Population. No participants were included in placebo-IV-SC group since no participant reached 90% depletion.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count</title>
          <description>Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.</description>
          <population>Safety Population. No participants were included in placebo-IV-SC group since no participant reached 90% depletion.</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="149" spread="62.8" lower_limit="69.0" upper_limit="200"/>
                    <measurement group_id="O3" value="100" spread="28.3" lower_limit="77.0" upper_limit="123"/>
                    <measurement group_id="O4" value="180" spread="39.2" lower_limit="140" upper_limit="229"/>
                    <measurement group_id="O5" value="211" spread="17.3" lower_limit="175" upper_limit="213"/>
                    <measurement group_id="O6" value="254" spread="45.3" lower_limit="244" upper_limit="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU</title>
        <description>The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.</description>
        <time_frame>Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU</title>
          <description>The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.</description>
          <population>Safety Population</population>
          <units>Percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="31.2"/>
                    <measurement group_id="O2" value="99.8" spread="0.0770"/>
                    <measurement group_id="O3" value="99.2" spread="0.787"/>
                    <measurement group_id="O4" value="99.7" spread="0.225"/>
                    <measurement group_id="O5" value="99.8" spread="0.182"/>
                    <measurement group_id="O6" value="99.8" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Positive for Anti-Drug Antibodies to MEDI-551</title>
        <description>A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.</description>
        <time_frame>Days 1, 29, 85 and 169</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO-IV-SC</title>
            <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI-551 30 Mg-IV</title>
            <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-551 60 Mg-SC</title>
            <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI-551 100 Mg-IV</title>
            <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-551 300 Mg-SC</title>
            <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI-551 600 Mg-IV</title>
            <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Positive for Anti-Drug Antibodies to MEDI-551</title>
          <description>A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the time of signature on informed consent through Day 169, SAEs were collected upto the long-term follow-up period (up to 18 months after early discontinuation visit or 24-week treatment period).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO-IV-SC</title>
          <description>Participants received either a fixed IV dose of placebo matching MEDI-551 on Days 1 and 15 or SC injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>MEDI-551 60 Mg-SC</title>
          <description>Participants received SC injection of 60 mg MEDI-551 on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI-551 100 Mg-IV</title>
          <description>Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="E4">
          <title>MEDI-551 300 Mg-SC</title>
          <description>Participants received SC injection of 300 mg MEDI-551 on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI-551 30 Mg-IV</title>
          <description>Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.</description>
        </group>
        <group group_id="E6">
          <title>MEDI-551 600 Mg-IV</title>
          <description>Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Armando Flor, MD, Director, Clinical Development</name_or_title>
      <organization>MedImmune</organization>
      <phone>301-398-1955</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

